Wegovy 0.25mg dosage: the starting dose explained

The myth: 0.25mg should be producing results by now

Patients often reach out after their first four weeks on Wegovy feeling disappointed. The scales haven't moved much, nausea has been an unwelcome companion, and the dose feels low. The conclusion they draw is that something is wrong, either with the medicine or with them.

Neither is true. Semaglutide's 0.25mg dose is deliberately below the threshold where meaningful appetite suppression kicks in. Its purpose is straightforward: to introduce the drug to your system slowly enough that the gastrointestinal side effects (nausea, loose stools, indigestion) stay manageable. Push straight to a higher dose and those effects become much harder to sit through. Novo Nordisk designed the titration schedule with this trade-off in mind, and every licensed prescriber follows it for good reason.

If you track your appetite honestly during this month, many people do notice subtle changes, a slightly earlier sense of fullness, a meal left unfinished. That is the drug beginning to work on GLP-1 receptors in the gut and brain. Weight reduction, though, is a later-stage story. The evidence base for Wegovy's weight-loss results, including the roughly 15% average body-weight reduction seen across 68 weeks in the STEP 1 trial published in the New England Journal of Medicine, came from participants who completed the full titration, not from the first four weeks.

So: if you want a closer look at what this opening stage involves, our guide to the Wegovy 0.25mg dose explains what the starting month is designed to do and what to expect from it. Patience here is not passive; it is part of the clinical strategy.

What to actually watch for in weeks one to four

Because the 0.25mg dose is low, side effects tend to be mild, but they are still real, and worth knowing before they appear rather than after. Nausea is the most frequently reported, typically peaking in the first day or two after each injection and fading before the next dose. Constipation, diarrhoea, burping and a general feeling of fullness are also common and are usually transient.

One practical thing worth doing: read the Patient Information Leaflet inside your Wegovy packaging before you give the first injection. It takes about three minutes and contains injection-site guidance, storage instructions, and a clear list of symptoms that warrant urgent medical attention, including severe, persistent stomach pain that spreads to the back, which can be a sign of pancreatitis. The MHRA's Yellow Card scheme allows you to report any suspected side effect directly; our prescribers also encourage patients to get in touch via aftercare if anything feels off.

Injection sites to rotate: upper arm, thigh, or abdomen. Check that your pen has been stored correctly (refrigerated between 2°C and 8°C) before each use. A quick thirty-second look at the pen's condition and the packaging date adds nothing to your morning routine but rules out the most avoidable problems.

If you are curious about how the 0.25mg pen itself is structured (the pre-set dose mechanism, how the needle covers work) there is a practical breakdown on our 0.25mg Wegovy pen guide.

How 0.25mg fits into the full Wegovy dose schedule

Wegovy follows a stepped titration: 0.25mg for four weeks, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg as the standard maintenance dose. Each step lasts roughly four weeks, so reaching maintenance takes around five months. The 7.2mg dose (approved by the MHRA in April 2026 and now available as a dedicated single-dose pen) sits above 2.4mg as the top of the schedule for those who need it, though it is not where anyone starts.

The jump from 0.25mg to 0.5mg is when patients typically begin to notice a more pronounced reduction in appetite. That is the dose where semaglutide's therapeutic effect starts to show clearly in most people. For context on what the full schedule looks like and what each step involves, the complete Wegovy dose guide covers the titration pathway in detail.

It is worth knowing that the prescriber's review sits between every dose step at nume. Nobody moves up automatically, a clinician reads your progress before any increase. If tolerability is the issue, staying at 0.25mg for longer than four weeks is a legitimate clinical choice, not a failure. On the other hand, if everything has been straightforward, your next pen will already be confirmed. How Wegovy doses are structured across treatment explains what that clinical review actually looks at.

For those thinking ahead to what the end of the dose ladder looks like, our page on the highest licensed Wegovy dose sets out what is known about the 7.2mg option and who it may be appropriate for.

Getting started: eligibility and the private route

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present, for example, high blood pressure, high cholesterol, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine whether a prescriber will approve treatment; your full clinical picture matters.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance, and waiting times can be long. Many people come to a private service instead. If you are weighing up that option, an honest look at what private treatment involves (including what is included in the price and what is not) is worth doing before you commit. Our Wegovy cost guide covers the private market factually, including what to look for beyond the headline number.

The 0.25mg dose is where every Wegovy journey begins, whatever the route. Starting it with an accurate picture of what it does (and what it doesn't) makes the first four weeks considerably easier to read. When you are ready to explore whether Wegovy could be right for you, check your eligibility with our prescribers through a free consultation.